CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hwail Pharm Co Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hwail Pharm Co Ltd (Parent)
57, Jeyakgongdan 3-gil, Hyangnam-eup
Phone: +82 313534101p:+82 313534101 HWASEONG, 18622  South Korea Fax: +82 25614897f:+82 25614897

Business Summary
HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201612/31/2016Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director Gyeong SukCho 63 3/24/2023 9/18/2020
Vice President, Director Yeong CheolJung 57 1/1/2011 1/1/2007
Vice President Yong HoJung 62
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 130 (As of 9/30/2013)
Outstanding Shares: 66,532,826 (As of 1/11/2023)
Shareholders: 2,703
Fax Number: +82 25614897


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023